Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
← catalyst calendarNCT06641089 · readout in 149 d
Sponsored by MoonLake Immunotherapeutics AG (industry) · MLTX — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
600estimated
Sites
142
Countries
Bulgaria, Canada, Czechia +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-15 | actual | When the study began enrolling |
| Primary completion | 2027-01-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-15 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Arthritis, Psoriatic
Interventions
- Drug: Sonelokimab
- Drug: Placebo
- Drug: Risankizumab
Primary outcome
what the primary-completion date above is the date OFResponse rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50)
measured Week 16 compared to placebo
Permalink · MLTX's whole pipeline · Catalyst calendar · Every registered study · What changed